Condition: Acute Heart Failure (AHF) · Sponsor: Hospital General de Agudos "Dr. Cosme Argerich"
The DIG-DICA trial is a randomized, controlled, open-label, single-center study designed to evaluate whether adding low-dose digoxin to optimal medical therapy after an episode of acute decompensated heart failure improves patients' clinical status and quality of life. The study enrolls adults with heart failure with reduced ejection fraction (HFrEF) who have recently stabilized after hospitalization or urgent care for decompensation. The primary aim is to determine whether digoxin increases the proportion of patients who are "Alive and Well" at 180 days-defined by achieving a Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score ≥75. The trial also explores effects on symptoms, functional capacity, biomarkers, renal function, and major cardiovascular events. The goal is to clarify whether modern low-dose digoxin provides meaningful clinical benefit in contemporary heart failure management.
This description comes directly from the study's public registry record.
Guillermo Ernesto Liniado, MD · +5491168615900 · guillermoliniado@yahoo.com.ar
Juan Alberto Gagliardi, MD · +5491154013300 · juanalbertogagliardi@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital General de Agudos Dr Cosme Argerich | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07321509